iRhythm Targets $890 Million–$895 Million In Sales As Zio Demand Exceeds Its Expectations

The higher outlook includes VitalConnect revenue, while litigation charges widened the quarterly loss.

Share
iRhythm Targets $890 Million–$895 Million In Sales As Zio Demand Exceeds Its Expectations

iRhythm Holdings, which helps doctors diagnose irregular heart rhythms through wearable cardiac monitors, raised its 2026 sales outlook to $890 million–$895 million Thursday, with Zio Monitor demand beating management’s expectations. The earnings release accompanying its SEC filing also raised the adjusted earnings margin forecast to 15.5%–16.0%, including the newly bought VitalConnect business.

Zio Volumes Lift Sales And Margins

Third-quarter sales totaled $221.6 million, rising 14.9% from $192.9 million a year earlier. iRhythm credited customer volumes and newer sales channels, with growth across cardiology, primary care and international markets.

“Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels,” said Quentin Blackford, iRhythm’s president and chief executive officer.

Gross profit increased 20.0% to $164.5 million from $137.1 million. More Zio services and approximately $3.1 million of one-time tariff refunds helped; gross margin reached 74.2%, improving 3.10 percentage points as efficiencies and product mix also contributed.

Adjusted earnings before interest, taxes, depreciation and amortization reached $51.2 million, a $29.6 million improvement from the year-earlier quarter. The corresponding margin was 23.1%.

Litigation Separates Loss From Adjusted Profit

Standard-accounting results went the other way. The quarterly net loss grew to $29.9 million, or $0.90 per diluted share, against $5.2 million, or $0.16 per share, a year earlier. Operating expenses reached $197.0 million versus $145.6 million, including $49.788 million in litigation settlement charges.

Those charges covered Baxter patent litigation and securities class-action settlements, net of expected insurance recoveries. The adjusted results excluded them, along with costs for business changes, intellectual-property litigation, impairments and the cybersecurity incident, among other adjustments.

Adjusted net income was $27.8 million, or $0.82 per diluted share, compared with a $2.0 million adjusted loss, or $0.06 per share. Adjusted operating expenses fell to $138.6 million from $141.4 million; management attributed the earnings improvement to sales growth and efficiency initiatives.

Cash generation also lagged the adjusted earnings result. Quarterly operating cash flow was $4.438 million versus $34.883 million a year earlier and included $50.0 million of Baxter settlement payments. After equipment and property purchases, free cash flow was negative $11.545 million, compared with positive $20.052 million.

VitalConnect Broadens The Monitoring Business

iRhythm completed its purchase of VitalConnect on October 5, adding an FDA-cleared mobile cardiac monitoring device. Its annual outlook includes approximately $16 million of expected VitalConnect sales between closing and year-end.

The existing Zio service combines a wireless patch that records heart signals for up to 14 days with cloud software. Trained technicians review reports before physicians receive them; customers include doctor practices and health systems, mainly in the United States, with a commercial presence in the United Kingdom, selected European countries and Japan.

iRhythm also submitted FDA applications to expand Zio Monitor use to children. The company said three published real-world studies covering more than 1.7 million patients supported its monitoring products, including improved Zio Monitor performance and diagnostic yield compared with Zio XT.

To support growth, iRhythm closed a $300 million secured revolving credit facility Tuesday. Unrestricted cash, cash equivalents and marketable securities stood at $560.7 million on September 30.

The year-end targets now include VitalConnect: management expects sales of $890 million–$895 million and an adjusted earnings-before-interest, taxes, depreciation-and-amortization margin of 15.5%–16.0%.

Sources

More on iRhythm Holdings

All iRhythm Holdings (IRTC) coverage →